Loading asset research
Adicet Bio Inc. Common Stock
ACETNasdaq · USD · StocksQuote as of · Exchange session not verified$9.56
+0.35%
Today
ACET
Loading 1D prices…
Market cap
$89.1M
Volume
119.3K
52w high
$17.4452w low
$6.01Company profile
Adicet Bio Inc. Common Stock
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Boston, MA, United States
Employees
102
Fiscal year end
1226
CIK
1720580
Session & valuation
Open$9.65
Previous close$9.53
Day high$9.80
Day low$9.38
30-day avg. volume95K
Outstanding shares9.4M
Diluted EPS-$16.95
Latest annual period
P/E (trailing)-0.56
P/E (forward)-2.36
Price / book0.85
Beta1.59
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MNOVMedicinova Inc Common Stock | $89.1M | $409.7K | +2928.79% | -$0.24 | +4.02% | Buy |
| RLYBRallybio Corporation Common Stock | $89.6M | $858K | -1046.39% | -$1.59 | +0.75% | Hold |
| ACRVAcrivon Therapeutics Inc. Common Stock | $85.7M | $0.00 | — | -$2.02 | -1.96% | Buy |
| VRCAVerrica Pharmaceuticals Inc. Common Stock | $84.3M | $35.6M | -50.31% | -$1.68 | -0.81% | Buy |
| FBIOFortress Biotech Inc. Common Stock | $84M | $63.3M | +58.49% | -$0.07 | -1.95% | Buy |